---
title: "Key facts: Assembly Biosciences Offers; ABI-6250 Expanded to PBC/PSC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287422492.md"
description: "Assembly Biosciences has priced approximately 3.36M shares at $26.50 and 415K pre-funded warrants at $26.499, targeting ~$100M. The company plans to expand oral ABI-6250 into cholestatic liver diseases (PBC, PSC), with a Phase 2 HDV trial set for Q4 2026 and a Phase 2 study for PBC/PSC starting Q1 2027. ABI-6250 has completed Phase 1a trials and received positive feedback from a pre-IND FDA meeting."
datetime: "2026-05-23T07:13:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287422492.md)
  - [en](https://longbridge.com/en/news/287422492.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287422492.md)
generator: "portal-rs"
---

# Key facts: Assembly Biosciences Offers; ABI-6250 Expanded to PBC/PSC

-   Assembly Biosciences priced ~3.36M shares at $26.50 and 415K pre-funded warrants at $26.499, aiming ~$100M; underwriters have 30-day option for 566,040 shares; close ~May 26, 2026.1
-   Assembly Biosciences to expand oral ABI-6250 from HDV into cholestatic liver diseases (PBC, PSC). Phase 2 HDV trial slated Q4 2026; Phase 2 basket study for PBC/PSC begins Q1 2027.2
-   Assembly Biosciences (ASMB): oral FXR agonist ABI-6250 completed Phase 1a with dose-dependent bile acid rises; chronic toxicology done; constructive pre-IND FDA meeting for cholestatic liver program3

### Related Stocks

- [ASMB.US](https://longbridge.com/en/quote/ASMB.US.md)

## Related News & Research

- [Assembly Bio to expand ABI-6250 into PBC and PSC; Phase 2 HDV trial set for Q4 2026](https://longbridge.com/en/news/287353780.md)
- [Assembly Biosciences Prices 3.35 Mln Shares At $26.50/shr; To Expand ABI-6250 Development; Stock Up](https://longbridge.com/en/news/287364187.md)
- [B. Metzler seel. Sohn & Co. AG Cuts Holdings in Amgen Inc. $AMGN](https://longbridge.com/en/news/296578862.md)
- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [Erqi Wang Discloses Investment at Jin Medical International with 6.77% Stake](https://longbridge.com/en/news/296651200.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**